Europe News Desk!!! According to the study published in The Lancet Infectious Diseases, a single dose of the Genios vaccine is 78 per cent effective against symptomatic mumps infection. Mpox (formerly known as monkeypox) is caused by a virus that is related to the virus that causes smallpox. Zynios, a modified vaccinia Ankara (MVA)-based live, non-replicating, two-dose vaccine, was approved for the prevention of monkeypox for adults at high risk of mpox infection. People need to get both doses of the vaccine for the best protection against mumps. The second dose should be given 4 weeks after the first dose.
But the study showed that the estimated one-dose vaccine efficacy against symptomatic mpox after at least 14 days was 78 percent. The researchers, including Jamie Lopez Bernal, Immunization and Vaccine-Preventable Diseases Division, UK Health Protection Agency, wrote that a single dose of MVA-BN (Genios) was highly protective against symptomatic mumps disease among at-risk (MSM), making it a rapid protection mpox became a useful tool for outbreak control when needed. For cases in which the number at highest risk of infection exceeds the supply of vaccine, there may be benefit in prioritizing delivery of the first dose. Mpox is a viral zoonotic disease that occurs primarily in the tropical rainforest regions of Central and West Africa and is occasionally exported to other regions. The World Health Organization (WHO) said last month that since January 1, 2022, there have been at least 85,765 confirmed cases of Mpox (monkeypox) in 110 countries and 1,382 probable cases.
–IANS
World News Desk!!!
KC/ANM